Samantha Chamberlain, APRN
Family · Owensboro, KYNPI 1811474067
Payments from drug & device makers
Across 261 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$775
- AbbVie$572
- Novo Nordisk$502
- Amgen$414
- GSK$270
- AstraZeneca$269
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,154100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 51 | $775 |
| AbbVie | 56 | $572 |
| Novo Nordisk | 36 | $502 |
| Amgen | 20 | $414 |
| GSK | 11 | $270 |
| AstraZeneca(2 entities) | 16 | $269 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $207 |
| Boehringer Ingelheim | 8 | $130 |
| Gilead | 1 | $98 |
| Corcept Therapeutics | 5 | $91 |
| Vanda Pharmaceuticals Inc. | 4 | $70 |
| Johnson & Johnson(2 entities) | 4 | $68 |
| Medtronic | 1 | $64 |
| Astellas Pharma US Inc | 3 | $63 |
| Nevro Corp. | 2 | $60 |
| Xeris Pharmaceuticals, Inc. | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 4 | $59 |
| Dexcom, Inc. | 2 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Exact Sciences | 2 | $28 |
| Insulet Corporation | 2 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 2 | $23 |
| Amryt Pharma Holdings Ltd | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,154 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 95 | $84,767 |
| OzempicSemaglutide | 24 | $25,221 |
| MounjaroTirzepatide | 21 | $20,827 |
| JanuviaSitagliptin Phosphate | 16 | $19,274 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $15,511 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $12,582 |
| TradjentaLinagliptin | 15 | $11,461 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $11,344 |
| MyrbetriqMirabegron | 15 | $10,408 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $7,333 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $6,657 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $4,813 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,083 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 103 | $2,473 |
| Doxepin Hcl | 54 | $2,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $130 | $103,561121 claims |
| Novo NordiskOzempic | $502 | $25,22124 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $270 | $23,92631 claims |
| Lilly USA, LLCMounjaro | $775 | $20,82721 claims |
| Astellas Pharma US IncMyrbetriq | $63 | $10,40815 claims |
| AstraZenecaSymbicort | $269 | $3,08315 claims |
| AbbVieSynthroid | $572 | $66217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.
Other family in Owensboro
- Jason SandersOwensboro$30K
- Melanie McCartyOwensboro$15K
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.